ESMO 2022: sự chú ý vào các lựa chọn điều trị mới nổi trong các khối u hệ thần kinh trung ương

Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. JAMA Oncol. 2020;6:1003. https://doi.org/10.1001/jamaoncol.2020.1024. Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase i cohorts of checkmate 143. Neuro Oncol. 2018; https://doi.org/10.1093/neuonc/nox208. Lim M, Weller M, Idbaih A, et al. Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022; https://doi.org/10.1093/neuonc/noac116. Klemm F, Maas RR, Bowman RL, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181:1643–1660.e17. https://doi.org/10.1016/j.cell.2020.05.007. Zhai L, Bell A, Ladomersky E, et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin Cancer Res. 2021;27:6514–28. https://doi.org/10.1158/1078-0432.CCR-21-1392. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86. https://doi.org/10.1038/s41571-020-00447-z. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2:992–7. https://doi.org/10.1038/nm0996-992. Reardon DA, Nayak L, Peters KB, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36:2006. https://doi.org/10.1200/JCO.2018.36.15_suppl.2006. Campian JL, Butt O, Huang J, et al. 278O Preliminary results of a phase II study of retifanlimab (PD‑1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295. Ann Oncol. 2022;33:S666. https://doi.org/10.1016/j.annonc.2022.07.412. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954–63. https://doi.org/10.1056/NEJMoa1707358. Birocchi F, Cusimano M, Rossari F, et al. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci Transl Med. 2022;14:eabl4106. https://doi.org/10.1126/scitranslmed.abl4106. Finocchiaro G, Eoli M, Farina F, et al. 284MO Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109). Ann Oncol. 2022;33:S669. https://doi.org/10.1016/j.annonc.2022.07.418. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‑year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. https://doi.org/10.1016/S1470-2045(09)70025-7. Weiss T, Puca E, Silginer M, et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci Transl Med. 2020;12:eabb2311. https://doi.org/10.1126/scitranslmed.abb2311. Weiss T, Look T, Puca E, et al. 285MO The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma. Ann Oncol. 2022;33:S669. https://doi.org/10.1016/j.annonc.2022.07.419. Wen P, de Groot JF, Battiste J, et al. 280O Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results. Ann Oncol. 2022;33:S667. https://doi.org/10.1016/j.annonc.2022.07.414. Buxton MB, Alexander BM, Berry DA, et al. GBM AGILE: a global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. J Clin Oncol. 2020;38:TPS2579. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS2579. Brenner AJ, Phillips WT, Bao A, et al. 277O The ReSPECT-GBMTM phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial. Ann Oncol. 2022;33:S666. https://doi.org/10.1016/j.annonc.2022.07.411. Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840–7. https://doi.org/10.1038/s41591-022-01935-8. Starzer AM, Berghoff ASS, Furtner J, et al. 281MO Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO‑1 trial. Ann Oncol. 2022;33:S668. https://doi.org/10.1016/j.annonc.2022.07.415.